Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Osteomyelitis - Overview
Osteomyelitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Osteomyelitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Osteomyelitis - Companies Involved in Therapeutics Development
Adaptive Phage Therapeutics Inc
BioVinc LLC
ContraFect Corp
Debiopharm Intertiol SA
Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
briva Therapeutics Plc
Sonoran Biosciences Inc
Telephus Medical LLC
Osteomyelitis - Drug Profiles
(tobramycin + vancomycin SR) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
afabicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologics for Corovirus Disease 2019 (COVID-19), Uriry Tract, Prosthetic Joint and Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BV-600022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceforanide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-296 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lefamulin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPH-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Osteomyelitis - Dormant Projects
Osteomyelitis - Product Development Milestones
Featured News & Press Releases
Mar 10, 2021: Adaptive Phage Therapeutics announces FDA clearance of IND application for PhageBank in treatment of diabetic foot osteomyelitis
Dec 11, 2017: Telephus Biosciences Appoints Patrick Vink, M.D., MBA, William Boyle, Ph.D., and Richard Proctor, M.D., as Company Advisors
Apr 08, 2016: Debiopharm Intertiol to present the latest findings on Debio 1450 at ECCMID
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Osteomyelitis, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Osteomyelitis, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Osteomyelitis - Pipeline by Adaptive Phage Therapeutics Inc, 2021
Osteomyelitis - Pipeline by BioVinc LLC, 2021
Osteomyelitis - Pipeline by ContraFect Corp, 2021
Osteomyelitis - Pipeline by Debiopharm International SA, 2021
Osteomyelitis - Pipeline by Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, 2021
Osteomyelitis - Pipeline by Nabriva Therapeutics Plc, 2021
Osteomyelitis - Pipeline by Sonoran Biosciences Inc, 2021
Osteomyelitis - Pipeline by Telephus Medical LLC, 2021
Osteomyelitis - Dormant Projects, 2021